Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 18 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 11007248

    Suppression of allergic lung inflammation and hyperreactivity

    The Regents of the University of California · Granted May 18, 2021 · Expires May 13, 2041

    granted

  2. US 11008548

    Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

    Precision BioSciences, Inc. · Granted May 18, 2021 · Expires May 13, 2041

    granted

  3. US 11001618

    Overexpression of FOXC1 to treat corneal vascularization

    Northwestern University · Granted May 11, 2021 · Expires May 6, 2041

    granted

  4. US 11001641

    Monoclonal antibody therapy for pancreas cancer

    PRECISION BIOLOGICS, INC. · Granted May 11, 2021 · Expires May 6, 2041

    granted

  5. US 11000595

    Modulators of PCSK9 expression

    Ionis Pharmaceuticals, Inc. · Granted May 11, 2021 · Expires May 6, 2041

    granted

  6. US 10995335

    RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted

  7. US 10988472

    Compounds and method for blocking transmission of malarial parasite

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 27, 2021 · Expires Apr 22, 2041

    granted

  8. US 10981986

    Fusions of antibodies to CD38 and attenuated interferon alpha

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  9. US 10975167

    Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinamide phosphoribotransferase

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted

  10. US 10973862

    Bifidobacterium longum for treating obesity and associated metabolic disorders

    PrecisionBiotics Group Limited · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted

  11. US 10975375

    Methods and compositions for regulation of transgene expression

    Sangamo Therapeutics, Inc. · Granted Apr 13, 2021 · Expires Apr 8, 2041

    granted

  12. US 10960070

    Prefusion coronavirus spike proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted

  13. US 10961297

    BTLA fusion protein agonists and uses thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted

  14. US 10954516

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted

  15. US 10953018

    Emulsion formulations of aprepitant

    Heron Therapeutics, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted

  16. US 10947310

    Fusion protein comprising apelin and an anti-APLNR antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  17. US 10942183

    Methods of detecting progesterone receptor and of detecting an expression level

    Regents of the University of Minnesota · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted

  18. US 10940214

    Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord

    The Regents of the University of California · Granted Mar 9, 2021 · Expires Mar 4, 2041

    granted

  19. US 10927373

    Compositions and methods for inhibiting gene expression of Hif2alpha

    Arrowhead Pharmaceuticals, Inc. · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted

  20. US 10927377

    Modulators of APOL1 expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted

  21. US 10927372

    Compositions and methods for modulating apolipoprotein C-III expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted

  22. US 10927141

    Salts and crystal forms of GABAA positive allosteric modulator

    PRAXIS PRECISION MEDICINES, INC. · Granted Feb 23, 2021 · Expires Feb 18, 2041

    granted

  23. US 10918703

    Fusion proteins for treating inflammatory diseases

    The Regents of the University of California · Granted Feb 16, 2021 · Expires Feb 11, 2041

    granted

  24. US 10912792

    Compounds and methods for modulating angiotensinogen expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.